BTT-3033

Cat. No.: IBDI-436302

BTT-3033 is an orally active conformation-selective inhibitor of α2β1 (EC50: 130 nM) by binding to the α2I domain. BTT-3033 inhibits platelet binding to collagen Ⅰ and cell proliferation, and induces cell apoptosis. BTT-3033 can be used in the research of prostate cancer, inflammation and cardiovascular disease.

Product Details

Target	Integrin | Apoptosis
Molecular Weight	465.50
Appearance	Solid
SMILES	O=C(NC1=CC=C(N(S(=O)(C2=CN(C3=CC=C(C=C3)F)N=C2)=O)C)C=C1)NC4=CC=CC=C4

Storage & Handling

Shipping	Room temperature in continental US. May vary elsewhere.
Storage	Powder: -20°C/3 years In solvent: -80°C/6 months; -20°C/1 month
Regulatory Status	This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use.